Edesa Biotech IPO-Jahr
Was ist das IPO-Jahr von Edesa Biotech?
IPO-Jahr von Edesa Biotech, Inc. ist 2010
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Edesa Biotech
Was macht Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Unternehmen mit ipo-jahr ähnlich Edesa Biotech
- Chigo hat IPO-Jahr von 2009
- Jade Road Investments hat IPO-Jahr von 2009
- Equity Metals hat IPO-Jahr von 2009
- Kerr Mines hat IPO-Jahr von 2009
- China e-Wallet Payment hat IPO-Jahr von 2009
- SQS India BFSI hat IPO-Jahr von 2009
- Edesa Biotech hat IPO-Jahr von 2010
- Broken Hill Prospecting hat IPO-Jahr von 2011
- Apollo Global Management Inc hat IPO-Jahr von 2011
- Hipo Resources hat IPO-Jahr von 2011
- Cogra 48 SA hat IPO-Jahr von 2011
- New Mountain Finance Corp hat IPO-Jahr von 2011
- Marfrig Global Foods SA hat IPO-Jahr von 2011